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PURPOSE. Posterior capsule opacification (PCO) is a common complication of cataract surgery.
In addition to improved surgical methods and IOL designs, it is likely additional agents will be
needed to improve patient outcomes. Presently no pharmacological agent is in clinical use to
prevent PCO. Here we investigate the putative ability of resveratrol (RESV), a naturally
occurring polyphenol, as a therapeutic agent.
METHODS. The human lens epithelial cell line FHL124, a human lens capsular bag model, and
central anterior epithelium were used as experimental systems. Standard culture was in 5%
fetal calf serum Eagle’s minimum essential medium; 10 ng/mL transforming growth factor-b2
(TGFb2) was used to induce fibrotic changes. A scratch wound assay was used to measure cell
migration and the patch assay was used to assess matrix contraction by FHL124 cells. Protein
expression was assessed by immunocytochemistry and Western blot and gene expression by
quantitative RT-PCR. In capsular bags, cell growth across the posterior lens capsule, capsular
wrinkling, and epithelial-to-mesenchymal transition were determined by image analysis.
RESULTS. In FHL124 cells, addition of 30 lM RESV significantly impeded cell migration in a
wound-healing assay. RESV significantly inhibited TGFb2-induced expression of the
myofibroblast marker alpha-smooth muscle actin (a-SMA) at both the message and protein
levels, as well as significantly inhibiting matrix contraction induced by TGFb2. In human
capsular bags, 30 lM RESV significantly inhibited cell growth. TGFb2-induced a-SMA
expression and capsular wrinkling were also significantly inhibited by RESV treatment. RESV
significantly suppressed expression of TGFb2-induced genes associated with fibrotic disease,
including matrix metalloproteinase-2 in FHL124 cells, capsular bags, and central anterior
epithelium.
CONCLUSIONS. RESV can counter PCO-related physiological events in two human lens model
systems. RESV therefore has the potential to be used as a candidate agent for the prevention of
PCO, which in turn could benefit millions of cataract patients.
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Cataract is the leading cause of blindness globally.
1 Defined
as any opacity of the eye lens, it is treatable only by surgical
intervention. Initially extremely successful in restoring vision,
this surgical procedure is the most commonly performed
operation in the developed world hugely burdening health care
budgets.2 Surgery involves removal of the cataractous lens fiber
mass and its replacement with an artificial IOL to restore free
passage of light along the visual axis.3 However, a significant
proportion of patients develop a secondary loss of vision
termed posterior capsule opacification (PCO) within 5 years of
surgery.2,4 In these patients, residual lens epithelial cells that
remain in the capsular bag following surgery, rapidly grow to
recolonize the anterior lens capsule and also migrate to the
previously cell-free posterior lens capsule. As the cells advance,
they also undergo epithelial-to-mesenchymal transition (EMT),
to become myofibroblastic cells expressing increased alpha-
smooth muscle actin (a-SMA) and produce excessive extracel-
lular matrix components. This aberrant extracellular matrix
deposition and capsule contraction/wrinkling, can also cause
light scatter and distort vision by impeding the free passage of
light along the visual axis.5
PCO is a fibrotic disease resulting from a wound-healing
response initiated by surgical trauma and breaching of the
blood-aqueous barrier. The profibrotic cytokine, TGFb, and its
signaling via the canonical (Smad) signaling pathway, is a
requirement for lens epithelial cells to undergo EMT, and it has
been strongly implicated in PCO development as well as
fibrotic responses in numerous other tissue types.6–8 The
predominant isoform in the human eye is TGFb2,9 and under
normal physiological conditions TGFb is present in an inactive,
latent form. Following the breaching of the blood-aqueous
barrier at cataract surgery, active levels of TGFb increase with
subsequent inflammation, elevating levels of activators of latent
TGFb, such as matrix metalloproteinases (MMPs) and thrombo-
spondin and aV integrins.10,11 These events lead to a sustained
TGFb activation, driving fibrotic events that lead to PCO.
PCO is treated by Nd:YAG capsulotomy, whereby a laser is
used to perforate the posterior lens capsule to create an
opening, again restoring the free passage of light to the retina.
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This procedure also risks complication and places further
burden on health care resources.6 PCO is therefore a
significant concern, with strategies to prevent or decrease its
occurrence required urgently. Remarkably, there is currently
no pharmacological agent with which to manage or prevent
PCO.
Resveratrol (RESV) is a naturally occurring polyphenolic
phytoalexin compound identified as being present in red wine
and to a lesser extent other foods, including peanuts and
berries, and has been long considered to have potential health
benefits.12 Previous studies have interestingly demonstrated an
ability of RESV to inhibit fibrotic events in various disease
models,13–17 and thus in the present study we aimed to
evaluate whether RESV could inhibit fibrotic events associated
with PCO, that is, cell proliferation, EMT, matrix production,
and matrix contraction.
METHODS
FHL124 Cell Cultures
FHL124 human lens epithelial cells were routinely cultured at
358C with 5% CO2, 95% air in Eagle’s minimum essential
medium (EMEM) (Gibco, Paisley, UK) supplemented with 5%
vol/vol fetal calf serum (FCS) (Gibco) and 50 lg/mL gentamicin
(Sigma-Aldrich, Dorset, UK). FHL124 cells were seeded at
50,000 cells per 35-mm cell culture dish for Western blot and
quantitative RT-PCR (QRT-PCR), 5000 cells per patch in 35-mm
cell culture dish for patch contraction assays, 50,000 cells per
patch in 35-mm cell culture dish for wound-healing assays, and
5000 cells per coverslip for immunocytochemistry.
Experimental conditions for FHL124 cells involved the
simple addition of RESV (Stratech Scientific Limited, Ely, UK)
versus control for 48 hours for the wound-healing assay. To
assess the effects of RESV (30 lM) on EMT, gene expression,
and contraction, the following protocol was adopted. Cells
were maintained in EMEM containing 5% FCS 6 30 lM RESV
for 24 hours. Following this period, TGFb2 was applied
directly to the selected cultures (half of each group) to give a
final concentration of 10 ng/mL. This resulted in four
experimental groups, which were control, RESV alone, TGFb2
alone, or RESV and TGFb2 treated. Cultures were maintained in
these conditions for 24 hours (QRT-PCR) or 48 hours (Western
blot and patch contraction assay). Coverslips were maintained
in conditions for 2 hours.
Wound-Healing Assay
FHL124 cells were seeded on a 35-mm tissue culture dish at
50,000 cells in 200 lL 5% FCS-EMEM and allowed to establish
over a 72-hour period, such that a distinct patch of cells was
observed. Following this period, a scratch was made through
the middle of the confluent sheet using a plastic pipette tip.
The medium was then replaced with fresh 5% FCS-EMEM to
remove cellular debris. Cells were then exposed to experi-
mental conditions. Indentations within the plastic dish were
made as a reference mark. The cells were then exposed to
experimental conditions and maintained for 48 hours. Images
were captured at 0-, 24-, and 48-hour time-points and wound
closure determined using image analysis software (ImageJ
1.48v; http://imagej.nih.gov/ij/; provided in the public domain
by the National Institutes of Health, Bethesda, MD, USA).
Quantitative RT-PCR
Total RNA was extracted from FHL124 cells, central anterior
lens epithelial samples, and human capsular bags cells using
the ReliaPrep RNA cell Miniprep System (Promega, Madison,
WI, USA) or the ReliaPrep RNA tissue Miniprep System
(Promega) as appropriate, following the manufacturer’s
instructions. RNA was quantified using a NanoDrop spectro-
photometer and cDNA generated using Superscript II reverse
transcriptase (Invitrogen, Carlsbad, CA, USA) and random
primers (Promega) following the manufacturers’ instructions.
Gene expression was quantified by real-time PCR with 18S
used as an endogenous control gene using predesigned
TaqMan probes (Life Technologies, Carlsbad, CA, USA)
(Table) and TaqMan PCR master mix (PCR Biosystems, London,
UK).
Western Blot Analysis
FHL124 cell lysates were obtained using M-PER buffer (Thermo
Scientific, Basingstoke, UK) supplemented immediately before
use with 10 lL/mL phosphatase and protease inhibitors and
0.5 M EDTA (Thermo Scientific). The bicinchoninic acid assay
(Thermo Scientific) was used to measure total protein content
to enable equal loading of protein onto 10% SDS-polyacryl-
amide gels. Proteins were transferred onto polyvinyl difluoride
(PVDF) membranes using a Trans-Blot Turbo Transfer System
(Bio-Rad, Watford, UK). PVDF membranes were blocked with
PBS containing 0.5% wt/vol nonfat dry milk and 0.05% vol/vol
Tween-20, hybridized with primary antibody against a-SMA
(Sigma-Aldrich) or b-actin (Cell Signaling Technology, Danvers,
MA, USA), followed by incubation with secondary antibody
conjugated with horseradish peroxidase (GE Healthcare, Little
Chalfont, UK). Proteins were detected using Clarity Western
ECL Substrate (Bio-Rad) and visualized with a ChemiDoc
imaging system (Bio-Rad).
Patch Contraction Assay
FHL124 cells were seeded as patches (four per 35-mm culture
dish) and allowed to grow until approximately 5 mm in
diameter and confluent. Cells were then placed in experimen-
tal conditions. On appearance of cell-free holes within patches,
cells were fixed with 4% formaldehyde for 30 minutes at room
temperature and washed three times for 5 minutes in PBS.
Patches were then stained with Coomassie brilliant blue
(Sigma-Aldrich) and washed with PBS to remove excess stain.
Patches were then imaged with a charge-coupled device
camera with (Synoptics, Cambridge, UK) and measured with
image analysis software (ImageJ, 1.48v).
Human Capsular Bag Model
Following the removal of corneo-scleral disks for transplanta-
tion processes, a simulated cataract operation was performed
on postmortem human donor eyes in a laminar flow hood as
previously described.18 Donor eyes were obtained with
written informed consent obtained from the next of kin. The
TABLE. Predesigned TaqMan Probe Sets for Genes of Interest
Gene
Name Protein Encoded
TaqMan Primer/
Probe Set
ACTA2 Alpha-smooth muscle actin (a-SMA) Hs00426835_g1
FN1 Fibronectin-1 (FN1) Hs01549976_m1
ITGA5 Integrin subunit alpha 5 (ITGA5) Hs1547673_m1
ITGAV Integrin subunit alpha V (ITGAV) Hs00233808_m1
MYLK Myosin light chain kinase (MLCK) Hs00364926_m1
MMP2 Matrix metalloproteinase 2 (MMP2) Hs01548727_m1
TGFB2 Transforming growth factor beta 2
(TGFb2)
Hs00234244_m1
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research was approved by the UK National Research Ethics
Committee (REC 04/Q0102/57) and followed the tenets of the
Declaration of Helsinki regarding the use of human donor
material. Match-paired capsular bags were maintained in 35-
mm tissue culture dishes, in the following match-paired
experimental conditions: 5% FCS-EMEM (control) versus 10
ng/mL TGFb2; control versus 30 lM RESV; 10 ng/mL TGFb2
versus 30 lM RESV and 10 ng/mL TGFb2, culture medium and
conditions were replaced at day 4 with ongoing observations
of cell growth performed using Nikon phase-contrast micro-
scope (Nikon, Tokyo, Japan) and a digital camera (Nikon).
Quantification of cell growth across the posterior lens capsule
was performed using image analysis software (ImageJ, 1.48v).
Capsular wrinkling/matrix contraction was assessed at exper-
imental endpoint (day 7) by analyzing modified dark-field
images of the central posterior capsule. Images were placed
through the find edges function on ImageJ. Edges associated
with wrinkles appear bright against a dark background. The
image is then subjected to thresholding, which allows
quantification.
Central Anterior Lens Epithelial Samples
Human central anterior lens epithelium samples (capsule and
cells) removed by capsulorhexis during simulated cataract
surgery were isolated. Each sample was halved and the four
pieces of tissue from the same donor were secured to
individual 35-mm tissue culture dishes using entomological
pins, cell-side up. Preparations were maintained at 358C in a 5%
CO2 atmosphere in either control conditions (EMEM supple-
mented with 5% vol/vol FCS and 50 lg/mL gentamicin), 30 lM
RESV alone, 10 ng/mL TGFb2 alone, or 30 lM RESV and 10 ng/
mL TGFb2. Preparations were maintained in experimental
conditions until endpoint (day 7), when samples were fixed in
4% formaldehyde for immunocytochemistry or maintained in
experimental conditions for 48 hours for gene expression
analysis by QRT-PCR.
Immunocytochemistry
FHL124 cells, human capsular bags, or central anterior lens
epithelial samples were fixed with 4% formaldehyde in PBS for
30 minutes followed by three washes in PBS for 5 minutes.
Samples were permeabilized with 0.5% vol/vol Triton X-100
(Sigma-Aldrich) for 30 minutes. Three washes in PBS contain-
ing 0.02% wt/vol BSA and 0.05% vol/vol commercial detergent
(IGEPAL; Sigma-Aldrich) were performed before blocking for
nonspecific binding sites with either normal donkey or normal
goat serum (1:50 in 1% wt/vol BSA in PBS) for 1 hour. Primary
antibodies against a-SMA (Sigma-Aldrich), fibronectin (Sigma-
FIGURE 1. Effect of RESV on wound closure by FHL124 cells. FHL124 cells were scratched to induce a wound before washing to remove debris and
addition of experimental conditions. Wound closure was assessed at 24 and 48 hours following the initial wound and maintained under control (5%
FCS-EMEM) conditions or treated with 30 lM RESV. (A) Representative images and (B) quantitative data established from multiple experiments (n¼
4). Wound closure was quantified as % initial wound. The data are presented as mean 6 SEM. *Significant differences between experimental
conditions (Student’s t-test; P  0.05).
Resveratrol Inhibits Wound Healing and Lens Fibrosis IOVS j September 2019 j Vol. 60 j No. 12 j 3865
Downloaded from iovs.arvojournals.org on 09/19/2019
Aldrich), and Smad2/3 (Cell Signaling Technology) were
diluted 1:200 in 1% BSA in PBS and applied overnight at 4
8C. Three further washes in PBS containing 0.02% wt/vol BSA
and 0.05% vol/vol IGEPAL were performed followed by
addition of secondary antibody (Alexa-Fluor 488-conjugated
donkey anti-rabbit or Alexa-Fluor 488-conjugated goat anti-
mouse) (Invitrogen) diluted 1:100 in 1% BSA in PBS) for 1 hour
protected from light at 378C in a humidified atmosphere.
Samples were then counterstained with 4 0,6-diamidino-2-
phenylindole (DAPI; Sigma-Aldrich) and Texas red-x-phalloidin
(Invitrogen). A further three washes in PBS containing 0.02%
wt/vol BSA and 0.05% vol/vol IGEPAL were performed
followed by mounting of samples onto glass microscope slides.
Samples were viewed with fluorescence microscopy (wide-
field microscope Zeiss Axioplan 2ie; Carl Zeiss Microscopy Ltd,
Cambridge, UK). Image quantification was performed using
image analysis software (ImageJ, 1.48v).
Statistical Analysis
One-way analysis of variance (ANOVA) with Tukey’s test was
performed to determine statistical differences between multi-
ple groups (SPSS 16.0; SPSS Inc., Chicago, IL, USA) and
Student’s t-test was used to determine statistical differences
when two experimental groups were being compared (Excel;
Microsoft, Redmond, WA, USA). A P value of  0.05 was
considered significant.
RESULTS
FHL124 Cell Line
To establish a working concentration of RESV, a Celltiter-Glo
viability assay (Promega) was performed (data not shown). No
loss in viability was observed at concentrations up to 30 lM
RESV, over a 72-hour culture period. Toxicity was, however,
observed with 100 lM. In the current study, we aimed to assess
the functional capabilities of RESV at noncytotoxic concentra-
tions in preventing PCO-related events, and thus 30 lM was
used as a working concentration. In the first instance, FHL124
cells were used as an initial model system.
Wound-Healing Assay
A wound-healing assay was used to assess FHL124 cell
migration and growth. RESV treatment significantly impeded
wound closure by FHL124 cells when compared with FHL124
cells maintained under control conditions (5% FCS-supple-
mented EMEM) (Fig. 1).
Epithelial-to-Mesenchymal Transition
To assess the effect of RESV on EMT, the myofibroblast marker,
a-SMA, was assessed at the message and protein level. FHL124
cell cultures were maintained in 5% FCS-EMEM 6 30 lM RESV
for 24 hours before TGFb2 was applied directly to the selected
cultures to give a final concentration of 10 ng/mL. The four
experimental groups were therefore control, RESV alone,
TGFb2 alone, or RESV and TGFb2 treated. Using quantitative
real-time PCR, it was found that the expression of ACTA2, the
gene encoding a-SMA protein, was significantly increased
following a 24-hour application of TGFb2, relative to non-
stimulated controls (Fig. 2A). Addition of RESV alone appeared
to reduce ACTA2 expression, but was not significantly different
from nonstimulated control. Notably, when cells were treated
with RESV in the presence of TGFb2, ACTA2 levels were
suppressed relative to TGFb2-treated cells, such that they were
equivalent to the control group (Fig. 2A).
At 48 hours, Western blots for a-SMA were performed (Figs.
2B, 2C). Protein levels of a-SMA were significantly elevated in
the TGFb2-treated group compared with those maintained in
control conditions. Again RESV alone appeared to suppress a-
FIGURE 2. Effect of RESV treatment on EMT. FHL124 cells were
maintained under control conditions (5% FCS-EMEM), treated with 30
lM RESV, 10 ng/mL TGFb2 or 30 lM RESV þ 10 ng/mL TGFb2. Cells
were treated with RESV 24 hours before addition of TGFb2. (A) ACTA2
gene expression was assessed by quantitative real-time RT-PCR, 24
hours post-TGFb treatment (n ¼ 5 6 SEM). (B) a-SMA protein
expression was determined by Western blot 48 hours post-TGFb
treatment (n¼ 3). The data are presented as mean 6 SEM. *Significant
difference between experimental conditions (ANOVA with Tukey’s
post hoc test; P  0.05).
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SMA protein, but as with gene expression, was not statistically
different. Treatment of cells with RESV countered the effects of
TGFb2 when applied together, such that levels were equivalent
to control treatment.
Matrix Contraction
FHL124 cell patches treated with TGFb2 demonstrated a
significantly greater proportion of cell-free areas within the
patch than observed under control conditions (Fig. 3).
Treatment with RESV alone did not generate cell-free regions
within the patch area. RESV treatment was found to suppress
TGFb2-induced patch contractions, which did not differ
significantly from controls (Fig. 3).
Gene Expression Changes
To assess the effect of RESV on genes associated with fibrosis,
FHL124 cell cultures were maintained in 5% FCS-EMEM 6
30lM RESV for 24 hours before TGFb2 was applied to selected
cultures for a further 24 hours. Gene expression of FN1,
ITGA5, ITGAV, MYLK, MMP2, and TGFB2 was assessed.
Treatment of FHL124 cells with TGFb2 significantly elevated
expression of FN1, ITGA5, ITGAV, MMP2, and TGFB2 from
levels observed in cells maintained under control conditions
(Fig. 4). No significant increase in MYLK was observed.
Treatment with RESV did not alter expression of any genes
studied when compared to controls (Fig. 4). Treatment of
FHL124 cells with TGFb2 in the presence of RESV resulted in
significantly less expression of ITGAV, ITGA5, MYLK, MMP2
and TGFB2 compared to cells treated with TGFb2 alone, such
that levels detected did not significantly differ from the control
group (Fig. 4). No significant reduction in FN1 expression was
observed in FHL124 cells treated with RESV and TGFb2
compared with TGFb2 treatment alone (Fig. 4).
Canonical TGFb/Smad Signaling Pathway
To assess the effect of RESV on TGFb2-induced Smad signaling,
FHL124 cells were maintained in 5% FCS-EMEM 6 30 lM RESV
for 24 hours before 10 ng/mL TGFb2 was applied to selected
cultures for a further 2 hours. Immunocytochemistry was
performed to assess Smad2/3 nuclear translocation in response
to these treatments (Fig. 5). FHL124 cells treated with RESV
alone did not demonstrate any change in nuclear translocation
of Smad2/3 compared with control treatments; however, a
significant increase in Smad2/3 nuclear translocation was
observed in TGFb2-treated cells compared with control and
RESV-treated cells. Cells treated with RESV and TGFb2 also
demonstrated a significant increase in Smad2/3 nuclear
translocation compared with control and RESV-treated cells;
these levels were not significantly different from cells treated
with TGFb2 alone (Fig. 5).
Human Capsular Bag Model
Human lenses were dissected from donor eyes and subjected
to simulated cataract surgery to create capsular bags that were
then cultured for 7 days in experimental conditions. Match-
paired experiments were conducted to compare untreated
FIGURE 3. RESV inhibits TGFb2-induced matrix contraction in FHL124 cells. FHL124 cells were maintained under control conditions (5% FCS-
EMEM), treated with 30 lM RESV, 10 ng/mL TGFb2 or 30 lM RESVþ 10 ng/mL TGFb2. Cells were treated with RESV 24 hours before addition of
TGFb2 with matrix contraction assessed by patch contraction assay. (A) Representative images of patches in different experimental conditions. (B)
Quantitative data established from multiple experiments (n ¼ 3). The data are presented as mean 6 SEM. *Significant difference between
experimental conditions (ANOVA with Tukey’s post hoc test; P  0.05).
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capsular bags maintained in control conditions versus those
treated with 10 ng/mL TGFb2, untreated versus 30 lM RESV
and capsular bags treated with 10 ng/mL TGFb2 versus 30 lM
RESVþ 10 ng/mL TGFb2. Ongoing observations of cell growth
across the posterior lens capsule were performed, with matrix
contraction and a-SMA expression as a marker of EMT assessed
at experimental endpoint (7 days).
Cell Growth Across Posterior Lens Capsule
Match-paired human capsular bags were first cultured in the
presence or absence of 10 ng/mL TGFb2. Cell coverage across
the posterior lens capsule in capsular bags maintained under
control conditions (EMEM containing 5% FCS) was 100% at day
7. Capsular bags treated with 10 ng/mL TGFb2 demonstrated a
retardation of cell growth across the posterior lens capsule,
which was significant from day 6 until experimental endpoint
at day 7 (Fig. 6).
To assess the effects of RESV treatment on cell growth
across the posterior lens capsule, match-paired capsular bags
were either maintained under control conditions or treated
with 30 lM RESV for a 7-day period. Cell coverage was again
measured daily. RESV treatment was found to suppress cell
growth across the posterior lens capsule, such that coverage
was significantly less than the untreated control from day 2
until experimental end point at day 7 (Fig. 6).
To investigate the effect of RESV treatment on TGFb2-
induced cellular changes in the capsular bag model, prepara-
tions were either cultured in the presence of 10 ng/mL TGFb2
or 30 lM RESV and 10 ng/mL TGFb2 with cell growth across
the posterior lens capsule observed. Cell growth across the
posterior lens capsule was found to be significantly attenuated
in capsular bags treated with RESV and TGFb2 compared with
those maintained in TGFb2 alone from day 3 through to
endpoint (day 7) (Fig. 6).
EMT/Matrix Deposition
Immunocytochemistry was used to assess the myofibroblast
marker a-SMA, and to assess matrix deposition using fibronec-
tin as a marker in cells present on the posterior lens capsule at
experimental endpoint (day 7). A significant increase in a-SMA
and fibronectin expression was noted in cells present on the
posterior capsule of capsular bags treated with 10 ng/mL
TGFb2 compared with untreated match-paired controls,
whereas no differences in a-SMA or fibronectin were observed
in capsular bags treated with 30 lM RESV compared with
untreated controls. Capsular bags treated with RESV and
TGFb2 demonstrated significantly less a-SMA and fibronectin
expression in cells present on the posterior capsule compared
with those treated with TGFb2 alone (Fig. 7).
Matrix Contraction/Capsular Wrinkling
Wrinkling of the posterior lens capsule (matrix contraction)
was assessed at experimental endpoint. In TGFb2-treated
capsular bags, a significant increase in capsular wrinkling/
matrix contraction was observed compared with untreated,
FIGURE 4. Effect of RESV on gene expression. FHL124 cells were maintained under control conditions (5% FCS-EMEM), treated with 30 lM RESV, 10
ng/mL TGFb2 or 30 lM RESVþ 10 ng/mL TGFb2. Cells were treated with RESV 24 hours before addition of TGFb2 with expression of FN1, ITGA5,
ITGAV, MYLK, MMP2, and TGFB2 assessed by real-time quantitative RT-PCR 24 hours posttreatment. The data are presented as mean 6 SEM; n¼ 5.
*Significant difference between experimental conditions (ANOVA with Tukey’s post hoc test; P  0.05).
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match-paired control preparations. No significant differences
in capsular wrinkling/matrix contraction was observed at
endpoint between RESV-treated and untreated capsular bags,
whereas treatment with 30 lM RESV in the presence of TGFb2
significantly reduced capsular wrinkling/matrix contraction
compared with that observed in capsular bags treated with
TGFb2 alone (Fig. 8).
Gene Expression Changes
Quantitative real-time PCR was used to assess whether RESV
treatment could influence TGFb2-induced changes in gene
expression in human capsular bags. Match-paired experiments
were performed with capsular bags cultured in 5% FCS-
supplemented EMEM and treated with 30 lM RESV and/or 10
ng/mL TGFb2, with ACTA2, FN1, MMP2, and TGFB2 gene
expression assessed 48 hours posttreatment (Fig. 9). Treatment
with 10 ng/mL TGFb2 induced a significant increase in ACTA2,
FN1, and MMP2 expression compared with untreated controls.
No difference in TGFB2 expression was noted with TGFb2
treatment compared with untreated controls. Treatment with
30 lM RESV caused a significant decrease in MMP2 and TGFB2
expression compared with untreated controls, with no
difference observed between RESV-treated capsular bags and
untreated controls in terms of ACTA2 or FN1 expression. In
match-paired capsular bags treated with TGFb2 or RESV þ
TGFb2, RESV treatment significantly reduced TGFb2-induced
expression of ACTA2, FN1, MMP2, and TGFB2.
Central Anterior Lens Epithelium
Central anterior lens epithelium samples consisting of a
circular portion of lens epithelial cells and central anterior
capsule measuring approximately 0.5 cm in diameter were
obtained during simulated cataract surgery on human donor
eye tissue. Central lens epithelium samples were cultured in
the presence of 30 lM RESV and/or 10 ng/mL TGFb2 or
maintained under control conditions for 7 days. a-SMA
expression was assessed by immunocytochemistry (Fig. 10).
Treatment with TGFb2 caused a significant increase in a-SMA
expression compared with all other treatment groups. No
changes in a-SMA expression were noted in central lens
epithelium samples treated with RESV alone compared with
controls or those treated with RESV þ TGFb2 compared with
those maintained under control conditions. The general
organization of the F-actin cytoskeleton also differed with
culture conditions, such that control samples presented a
regular cobblestone appearance, whereas TGFb treatment
increased the presence of stress-fibers. Treatment with RESV
in the presence or absence of TGFb resulted in a pattern
similar to controls.
Quantitative real-time PCR was also used to assess whether
RESV treatment could influence TGFb2-induced gene expres-
sion changes in central anterior lens epithelium samples.
Match-paired experiments were performed with central
anterior lens epithelium samples cultured in 5% FCS-supple-
mented EMEM and treated with 30 lM RESV and/or 10 ng/mL
TGFb2, with ACTA2, FN1, and MMP2 gene expression assessed
48 hours posttreatment (Fig. 11). Treatment with 10 ng/mL
FIGURE 5. RESV treatment does not prevent TGFb2-induced Smad2/3 nuclear translocation. FHL124 cells were maintained under control
conditions (5% FCS-EMEM), treated with 30 lM RESV, 10 ng/mL TGFb2 or 30 lM RESVþ 10 ng/mL TGFb2 for 2 hours. (A) Immunocytochemistry
was performed to assess nuclear translocation of Smad2/3 (green). Cells were counterstained for chromatin with DAPI (blue). (B) The data are
presented as mean 6 SEM; n¼ 3. *Significant differences between experimental conditions (ANOVA with Tukey’s post hoc test; P  0.05).
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TGFb2 induced significant increases in ACTA2, FN1, and MMP2
expression compared with untreated controls. Treatment with
30 lM RESV caused a significant decrease in ACTA2 and MMP2
expression compared with untreated controls, with no
difference noted in FN1 expression. In central anterior lens
epithelium samples treated with TGFb2 or RESV þ TGFb2,
RESV treatment significantly reduced TGFb2-induced expres-
sion of ACTA2, FN1, and MMP2 expression.
DISCUSSION
PCO remains an important and common complication of
cataract surgery.2 Numbers undergoing surgery will increase as
the population ages, and the need for better management of
PCO is heightened. Improved IOL design has restricted PCO
progression to some degree, but the problem is far from
resolved.19 Application of agents that can disrupt PCO in
addition to improved IOL designs will provide the best
opportunity to maintain a good level of visual quality after
cataract surgery. The present body of work has demonstrated
that the naturally occurring polyphenol, RESV, can retard
growth/migration, reduce EMT, and suppress matrix contrac-
tion in human cell and tissue culture models of PCO, and thus
indicates that RESV could serve as a useful therapeutic agent
for this prevalent condition.
RESV was first isolated from hellebore roots and more
recently found to be present in red wine.20 RESV has since
been identified as having therapeutic potential in the
prevention of various diseases, including cancers, cardiovas-
cular disease, and neurological disorders.21 In addition to its
reported antioxidant and anti-inflammatory properties,21 RESV
has been demonstrated to inhibit fibrosis in various disease
models ranging from the liver,13 gastrointestinal tract,14 lung,22
pancreas,15 skin,23 urinary tract,16 and retina.17 Evaluating its
potential ability to prevent PCO, which is a fibrotic disorder,
was therefore a logical step. PCO is characterized by growth
and migration of lens epithelial cells that remain following
cataract surgery to the previously cell-free posterior lens
capsule. These cells can undergo EMT, secrete excessive
FIGURE 6. RESV inhibits lens cell growth across the posterior lens capsule of human capsular bags. (A) Representative images and (B) quantitative
data established from multiple experiments. Match-paired capsular bags were placed into experimental conditions comparing control (5% FCS-
EMEM) versus 10 ng/mL TGFb2, control versus 30 lM RESV and 10 ng/mL TGFb2 versus 30 lM RESVþ 10 ng/mL TGFb2. Experimental conditions
were replaced at day 4 and cell growth across the posterior lens capsule analyzed daily by phase-contrast microscopy and image analysis software.
The data are presented as mean 6 SEM; n ¼ 6. *Significant difference between experimental conditions (Student’s t-test; P  0.05).
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FIGURE 7. RESV suppresses TGFb2-induced a-SMA and fibronectin expression in cells present on the posterior lens capsule of human capsular
bags. (A, C) Representative images and (B, D) quantitative data established from multiple experiments. a-SMA expression or fibronectin (green) was
assessed at experimental endpoint (day 7) by immunocytochemistry. Match-paired capsular bags were placed into experimental conditions
comparing control (5% FCS-EMEM) versus 10 ng/mL TGFb2, control versus 30 lM RESV, and 10 ng/mL TGFb2 versus 30 lM RESV þ 10 ng/mL
TGFb2. Experimental conditions were replaced at day 4. The data are presented as mean 6 SEM; n ¼ 3. *Significant difference between
experimental conditions (Student’s t-test; P  0.05).
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extracellular matrix components, and cause the posterior lens
capsule to contract or wrinkle.5,10 Using human cell and tissue
culture models allowed the effects of RESV on these features of
PCO to be assessed.
The present body of work has revealed RESV is able to
impede lens cell migration and wound healing. This is
important in the context of PCO progression, as the invasion
of cells within the visual axis provides the platform on which
further light-scattering events can result. It should be pointed
out that antimigratory actions of RESV were less pronounced in
our cell-line assays than in the tissue culture capsular bag
model. Previous work also has indicated that RESV can affect
migration of various cancer cells,24,25 and it has been suggested
that RESV may inhibit migration of ARPE-19 retinal epithelial
cells.26
RESV treatment resulted in a significant reduction in
transdifferentiation from lens epithelial cells to myofibroblasts.
The profibrotic cytokine, TGFb is heavily involved in the
development of PCO and EMT in particular.5,10 We have
demonstrated the ability of RESV to significantly inhibit the
TGFb2-induced expression of the myofibroblast marker, a-SMA,
in a human lens cell line (FHL124) and human capsular bags
following simulated cataract surgery, indicating the ability of
RESV to prevent the EMT associated with PCO. EMT is also
believed to play an important role in another lenticular
condition, anterior subcapsular cataract (ASC).10 This is linked
to modification of the lens epithelium and is characterized by a
fibrotic plaque that obscures the light path. TGFb is also
implicated in this condition, and it has been reported that ASC
samples express increased TGFb and TGFb receptors along
with the matrix components fibronectin and type I collagen
and a-SMA.27 Addition of TGFb to cultured human anterior lens
epithelium resulted in a dramatic increase in EMT. This TGFb-
induced change was ablated by RESV treatment. These results
in the human lens reflect findings in other ocular tissues. For
example, Ishikawa et al.,17 investigating proliferative vitreoret-
inopathy, showed that RESV inhibited TGFb2-induced EMT of
RPE cells, countering a reduction of epithelial markers E-
cadherin and ZO-1 by TGFb2 and TGFb2-induced increase in a-
SMA expression.
Deformation of the lens capsule can lead to light scatter. It
has been demonstrated in previous works that TGFb can
promote matrix modifications of the capsular bag that generate
matrix contraction/wrinkles and are reflective of those
observed in postmortem specimens.28 Contraction or wrin-
kling of the posterior lens capsule ultimately results in the
obstruction of the free passage of light to the retina and
secondary loss of vision. RESV importantly was found to
prevent matrix contraction/wrinkling of the posterior capsule
and in a human lens cell contraction assay. Other works also
have demonstrated effects of RESV on TGFb-induced contrac-
tion of RPE cells using a collagen gel contraction assay.26
The canonical Smad signaling pathway plays an important
role regarding EMT in the lens. Saika et al.29 demonstrated that
FIGURE 8. RESV suppresses TGFb2-induced matrix contraction/posterior capsule wrinkling. (A) Representative images and (B) quantitative data
established from multiple experiments. Capsular wrinkling was assessed at experimental endpoint (day 7) by image analysis. Match-paired capsular
bags were placed into experimental conditions comparing control (5% FCS-EMEM) versus 10 ng/mL TGFb2, control versus 30 lM RESV, and 10 ng/
mL TGFb2 versus 30 lM RESVþ 10 ng/mL TGFb2. Experimental conditions were replaced at day 4. The data are presented as mean 6 SEM; n¼ 7
(5% FCS-EMEM versus 10 ng/mL TGFb2 and control versus 30 lM RESV) or n ¼ 6 (10 ng/mL TGFb2 versus 30 lM RESV þ 10 ng/mL TGFb2).
*Significant difference between experimental conditions (Student’s t-test; P  0.05).
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Smad3 knockout mice presented significantly smaller anterior
subcapsular plaques relative to wild-type. In the present study,
we did not find a significant inhibition of Smad2/3 transloca-
tion to the nucleus in response to TGFb in the presence or
absence of RESV. This suggests that RESV does not affect
initiation of the Smad signaling pathway, but may affect
transcriptional activity. It is known that both Smad2 and 3
recruit p300 histone acetyltransferase to the MHII domain,
which is believed to facilitate transcriptional activity to take
place.30 RESV is reported to increase Sirtuin activity,31 and it is
reported that Sirt1 and 2 can inhibit p300 function,32 which
could explain the downregulation in Smad-associated fibrotic
genes observed in the current study.
TGFb is also known to signal through Smad-independent
pathways. These pathways, involving ERK and p38 for example,
are stimulated in human lens cells by TGFb.33 Work in
nonhuman systems has also suggested that ERK plays an
important role in the initiation of EMT in the lens.34 Moreover,
it has been suggested that matrix contraction can be regulated
by Smad-independent pathways without the requirement for
EMT.35 To test the putative therapeutic benefit of RESV in our
studies, we maintained cells in serum-culture medium as a
baseline to drive growth and migration. Although this provides
an excellent test for therapeutic assessment, the ability to
identify changes in TGFb-induced Smad-independent signaling is
confounded, as serum contains many factors that can drive these
pathways. This does not diminish the potential involvement of
Smad-independent signaling pathways in the PCO-related events
observed, but extensive inhibition experiments will be required
and will form the basis for future studies.
FIGURE 9. RESV suppresses expression of genes associated with TGFb2 signaling in human capsular bags. Human capsular bags were treated
comparing control (5% FCS-EMEM) versus 10 ng/mLTGFb2, control versus 30 lM RESV, and 10 ng/mLTGFb2 versus 30 lM RESVþ10 ng/mLTGFb2
for 2 days. Real-time quantitative PCR was performed to assess changes in gene expression. The data are presented as mean 6 SEM; n ¼ 4.
*Significant difference between experimental conditions (Student’s t-test; P  0.05).
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To further ascertain a mechanism that underpins the
therapeutic benefit of RESV, we chose to observe changes in
gene expression of the FHL124 cell line, central anterior lens
epithelium, and capsular bag cultures under different culture
conditions. A number of these genes were markers for specific
PCO-related events. However, one of the genes investigated,
MMP2, could feasibly play a role in multiple physiological
events attributed to PCO.
A normal healthy lens epithelium within an intact lens has a
relatively low-level expression of MMP2. This is also a general
pattern observed for other secreted MMP family members.36
However, culture or injury can provoke changes in expression
level.36 Previous work37 and the present study have shown
MMP2 to be upregulated in FHL124 cells following TGFb2
treatment. The work in the current study demonstrates
increased MMP2 gene expression in human capsular bag
preparations in response to TGFb2. This finding complements
previous work that showed MMP2 protein was secreted at a
greater level by capsular bags treated with TGFb2.28 Moreover,
ex vivo cultures (removed from donors who had previously
had surgery and developed PCO) are also known to secrete
MMP2 when cultured.28 MMPs are known to cleave extracel-
lular matrix (ECM) components, such as collagen IV, a key
component of the lens capsule, altering the ECM to expose
sites of cellular attachment,37–39 which could allow migration
of lens epithelial cells. RESV-mediated suppression of MMP2
expression could provide an explanation as to how RESV is
able to inhibit lens epithelial cell growth across the posterior
lens capsule. In support of the present study’s findings,
previous work40 demonstrated that inhibition of MMPs with
a broad-spectrum MMP inhibitor prevented the migration of
lens epithelial cells onto the posterior lens capsule of cultured
human lens capsules. In addition, it also has been proposed
that the lens capsule acts as a reservoir for growth and survival
FIGURE 10. RESV suppresses EMT in human central lens epithelial cells. (A) Representative images and (B) quantitative data established from
multiple experiments. Central lens epithelium samples were maintained in control conditions or treated with 30 lM RESV, 10 ng/mL TGFb2, or 30
lM RESVþ 10 ng/mL TGFb2 with expression of a-SMA (green) assessed by immunocytochemistry. Expression was quantified using image analysis
software. The data are presented as mean 6 SEM; n¼ 3 *Significant difference between experimental conditions (ANOVA with Tukey’s post hoc
test; P  0.05).
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factors, such as FGF-2, which are required for lens epithelial
cell proliferation, migration, and differentiation. MMP2 has
been found to facilitate the release of FGF-2 from the lens
capsule41 and thus provides another potential route by which
RESV may influence lens epithelial cell migration across the
posterior lens capsule. FGF2 also has been demonstrated to
exacerbate TGFb2-induced ASC formation in cultured rat
lenses,42 suggesting how suppression of MMP2 expression by
RESV may be further involved in subduing events associated
with PCO.
MMPs, principally MMP2 and MMP9, have been implicated
in the activation of latent TGFb to its active form, thus enabling
TGFb signaling to occur and drive the EMT process.43 TGFb is
produced by FHL124 and lens cells within the capsular bag.
This de novo pool of TGFb could therefore further advance
changes observed in the capsular bag cultures. If this autocrine
source of TGFb is to contribute, then activation will be
required. It is therefore possible that RESV could lead to lower
total and active levels of TGFb within the capsular bag, which
could contribute to the therapeutic benefits of RESV in PCO
prevention in our models.
Furthermore, the importance of MMP2 in contraction of the
extracellular matrix, specifically in the human lens, has been
demonstrated. Eldred and colleagues37 revealed that MMP2
levels are increased with TGFb2 treatment, and that MMP2
activity is critical for TGFb2-induced matrix contraction in
human lens cells and the human capsular bag model,
importantly suggesting an important role of MMP2 in PCO.
The contribution of MMPs in EMT and fibrotic disease also
has been further highlighted in mouse models of ASC. Korol at
al.44 found that in mouse, MMP9, rather than MMP2 is
important for TGFb-induced ASC formation. This appears to
differ from the human system in which MMP2 plays a greater
role, but nevertheless it would appear that the gelatinases
(MMP2 and 9) contribute to both ASC and PCO. Consequently
the suppression of MMP2 by RESV is likely to have therapeutic
benefit as a result of reduced EMT. It is important, however, to
consider how RESV could be used to treat or prevent lens
pathologies. In the case of ASC, this will require long-term
application and most likely will require eye drops or be taken
as a dietary supplement. RESV is a compound that exhibits
rapid metabolism following oral consumption with limited
bioavailability,45 with one study finding no detectable RESV
present in the aqueous or vitreous humors following oral
consumption.46 Despite much being made of RESV content in
certain foods and red wine,47 the authors consider that RESV
FIGURE 11. RESV suppresses expression of genes associated with TGFb2 signaling in central anterior lens epithelium. Samples were treated
comparing control (5% FCS-EMEM) versus 10 ng/mLTGFb2, control versus 30 lM RESV, and 10 ng/mLTGFb2 versus 30 lM RESVþ10 ng/mLTGFb2
for 2 days. Real-time quantitative PCR was performed to assess changes in gene expression. The data are presented as mean 6 SEM; n¼ 4 (control
versus 10 ng/mL TGFb2) or n ¼ 3 (control versus 30 lM RESV or TGFb2 versus RESV þ TGFb2). *Significant difference between experimental
conditions (Student’s t-test; P  0.05).
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would have little therapeutic benefit as an oral therapy to
prevent events associated with PCO. It would therefore appear
that delivery to treat ASC would require eye drops, but the
dosage and treatment regimen would require detailed pharma-
cological profiling and development to ensure adequate levels
reach the lens, while preserving the integrity of other ocular
tissues, in particular the cornea.
In the case of PCO, the scope for drug delivery is greater.
Cataract surgery is invasive, and drugs can be applied directly
to the lens cells during surgery using closed drug delivery
systems48,49 or through modification of the IOL or a tension
ring,50–52 and these options will be explored in the future.
The present study has shown that RESV can prevent three
events pivotal for PCO development: cell proliferation/
migration, EMT, and contraction of the posterior lens capsule.
RESV is an exciting therapeutic candidate to better manage
PCO after cataract surgery, which could improve the well-
being of millions.
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